IMA (Ifosfamide, Mesna, Adriamycin) Chemotherapy Protocol

What Is IMA?

• I – Ifosfamide (Ifex)
• M – Mesna (Mesnex)
• A – Adriamycin (Doxorubicin)

The IMA protocol, described as chemotherapy with ifosfamide, Adriamycin (doxorubicin), and mesna, is used particularly for rare connective and supporting tissue tumors such as soft-tissue sarcomas (STS) and osteosarcoma.

It may be used to reduce tumor burden, control metastases , or shrink a tumor before surgery (neoadjuvant treatment).

IFOSFAMIDE

• Class: Alkylating agent (oxazaphosphorine)
• Mechanism: Causes DNA cross-linking, leading rapidly dividing cancer cells to undergo apoptosis (cell death).

ADRIAMYCIN (DOXORUBICIN)

• Class: Anthracycline antibiotic
• Mechanism: Binds DNA, inhibits topoisomerase II, and generates DNA-damaging free radicals.

MESNA

• Class: Uroprotectant
• Mechanism: Binds acrolein, a urotoxic metabolite, protecting the bladder from hemorrhagic cystitis caused by toxic ifosfamide metabolites.

Indications for IMA

• Soft-Tissue Sarcomas (STS)
  • Used in localized or metastatic disease.
  • Particularly effective in high-grade sarcomas.
• Osteosarcoma
  • Used for bone tumors, particularly before surgery (neoadjuvant) or afterward (adjuvant treatment).
  • May be selected for disease control in patients with lung metastases.
• Other Solid Tumors
  • May also be used for certain bone and soft-tissue tumors, such as Ewing sarcoma and rhabdomyosarcoma.

When Is IMA Used?

• Locally Advanced or Metastatic Disease: To reduce tumor burden and slow progression.
• Neoadjuvant Treatment: To shrink a tumor before surgery.
• Adjuvant Treatment: To reduce recurrence risk after surgery.
• Palliative Treatment: To prolong life and control symptoms in disseminated disease.

Treatment Schedule

Premedication

• Ondansetron: 8 mg orally (PO) or IV, 30 to 60 minutes before chemotherapy.
• Dexamethasone: 8 mg PO/IV, 30 to 60 minutes before chemotherapy, followed by 4 mg PO/IV every 12 hours after chemotherapy for 2 doses.
• Aprepitant: 125 mg PO on day 1, 30 to 60 minutes before chemotherapy, followed by 80 mg PO daily on days 2 and 3.
• Lorazepam: 1 mg every 4-6 hours for nausea, sleep, or restlessness.
• Prochlorperazine for Nausea or Vomiting: 10 mg PO every 4-6 hours.

Medication

• Doxorubicin: 60 mg/m2 IV infusion over 5-20 minutes on day 1.
• Ifosfamide: 2500 mg/m2 IV infusion over more than four hours on days 1, 2, and 3.
• Mesna: IV over more than four hours on days 1, 2, and 3, followed by two IV or same-day oral doses. Give 1/3 of the 2500 mg/m2 dose with ifosfamide and infuse the remaining 2/3 over 8 hours.

Estimated Total Infusion Time:

• An outpatient visit may last 5 to 6 hours daily if the patient leaves after ifosfamide and takes oral mesna at home.
• Giving two IV mesna doses after ifosfamide at the center may take 9 or 10 hours.
• Because of prolonged infusions and side effect management, the patient should remain in hospital for 4 to 5 days.
• IMA is given every 21 days , constituting a cycle. Depending on disease stage, cycles may be repeated up to six times. Treatment may last up to six months according to response, tolerability, and the planned number of cycles.

Side Effects

Each medicine in a combination has its own effects. The most commonly reported effects of IMA in trials are:

• Nausea (84%)
• Fatigue (84%)
• Hair loss (67%)
• Vomiting (62%)
• Neutropenic fever (46%)
• Constipation (43%)
• Decreased appetite (37%)
• Low red blood cell count (35%)
• Mucositis (34%)
• Low platelets (33%)
• Diarrhea (30%)
• Breathlessness (29%)
• Cough (25%)
• Weight loss (20%)
• Fever (19%)
• Bleeding (18%)
• Headache (17%)
• Fluid retention (17%)
• Blood clots (13%)
• Skin rash (9%)
• High blood pressure (5%)

Trials report that an average of 17% stopped treatment because of side effects. Severity varies between people and over time. Preventive medicines (prophylaxis) can prevent some effects.

Precautions and Monitoring

• Regular laboratory testing is required before and during treatment.
• Daily urinalysis checks for blood in urine.
• Assess patients before each dose for neurotoxicity and monitor mental status.
• Perform ECG/echocardiography before and during treatment to monitor cardiotoxicity.
• G-CSF (filgrastim) support may be given for bone marrow suppression and neutropenia.

Repeat imaging before treatment and after every two cycles to assess effectiveness. The doctor may revise the plan according to blood tests and imaging.